F. Poordad
About
F. Poordad is a scholar working on Hepatology, Epidemiology and Genetics.
According to data from OpenAlex, F. Poordad has authored 62 papers receiving a total of 895 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hepatology, 34 papers in Epidemiology and 12 papers in Genetics. Recurrent topics in F. Poordad's work include Hepatitis C virus research (45 papers), Liver Disease Diagnosis and Treatment (19 papers) and Hepatitis B Virus Studies (18 papers). F. Poordad is often cited by papers focused on Hepatitis C virus research (45 papers), Liver Disease Diagnosis and Treatment (19 papers) and Hepatitis B Virus Studies (18 papers). F. Poordad collaborates with scholars based in United States, Germany and France. F. Poordad's co-authors include Clifford A. Brass, E. Läwitz, Ira M. Jacobson, Mark Sulkowski, Janice K. Albrecht, Barry Bernstein, Navdeep Boparai, Stefan Zeuzem, Margaret Burroughs and K.V. Kowdley and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.
In The Last Decade
F. Poordad
58 papers receiving 858 citations
Peers
F. Poordad
Sergio Rodríguez‐Tajes Spain
Cheng‐Chao Liang Taiwan
Stanislas Pol France
Petr Husa Czechia
J. Kirschner Germany
Carlo Crivellaro Italy
C. Cornù Belgium
C. Manegold Germany
Citations per year, relative to F. Poordad F. Poordad (= 1×)
peers
Roberto José de Carvalho‐Filho
Countries citing papers authored by F. Poordad
Since
Specialization
Citations
This map shows the geographic impact of F. Poordad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Poordad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Poordad more than expected).
Fields of papers citing papers by F. Poordad
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by F. Poordad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Poordad. The network helps show where F. Poordad may publish in the future.
Co-authorship network of co-authors of F. Poordad
This figure shows the co-authorship network connecting the top 25 collaborators of F. Poordad. A scholar is included among the top collaborators of F. Poordad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Poordad. F. Poordad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gane, E., F. Poordad, Joaquin Valdes, et al.. (2017). Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Journal of Hepatology. 66(1). S306–S306.
2.
Kwo, Paul Y., F. Poordad, Ariel Porcalla, et al.. (2016). Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies. Journal of Hepatology. 64(2). S809–S809.
3.
Gschwantler, Michael, G.J. Dore, M.P. Manns, et al.. (2014). Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials. Zeitschrift für Gastroenterologie. 52(5). 53.
4.
Zeuzem, Stefan, F. Poordad, J.‐P. Bronowicki, et al.. (2013). 1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS. Journal of Hepatology. 58. S576–S577.
5.
Kowdley, K.V., E. Läwitz, F. Poordad, et al.. (2013). 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY. Journal of Hepatology. 58. S2–S2.
6.
Poordad, F., E.J. Lawitz, K. Rama Reddy, et al.. (2012). 1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN. Journal of Hepatology. 56. S559–S559.
7.
Zeuzem, Stefan, Thomas Berg, Edward Gane, et al.. (2012). 2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL. Journal of Hepatology. 56. S1–S2.
8.
Bronowicki, J.-P., Mitchell Davis, S. Flamm, et al.. (2012). 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS. Journal of Hepatology. 56. S6–S6.
9.
Dusheiko, Geoffrey, Nezam H. Afdhal, Edoardo G. Giannini, et al.. (2012). 60 RESULTS OF ENABLE 2, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AND PEGINTERFERON ALFA-2B TREATMENT IN PATIENTS WITH HEPATITIS C AND THROMBOCYTOPENIA. Journal of Hepatology. 56. S27–S27.
10.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2011). FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA. UCL Discovery (University College London).
11.
Zeuzem, Stefan, John M. Vierling, Rafael Esteban, et al.. (2011). 484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S198–S199.
12.
Thompson, Alexander, Paul J. Clark, Hans L. Tillmann, et al.. (2011). Il28B C/c Genotype Is Predictive of >= 1 Log10 Iu/ml Reduction in Plasma Hcv Rna After 4 Weeks of Peginterferon (Pegifn) and Ribavirin (Rbv) Therapy: Implications for the Use of the Lead-In Strategy for Direct-Acting Antiviral-Based Treatment Regimens. Hepatology. 54.
13.
Flamm, S., E. Läwitz, Ira M. Jacobson, et al.. (2011). 1366 HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN. Journal of Hepatology. 54. S541–S542.
14.
Berg, Thomas, John G. McHutchison, Nathalie Adda, et al.. (2010). 4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR. Journal of Hepatology. 52. S2–S2.
15.
Poordad, F., John G. McHutchison, Thomas Berg, et al.. (2010). 290 EARLY VIROLOGICAL RESPONSE PROFILES WITH TELAPREVIR (T) IN COMBINATION WITH PEGINTERFERON-ALFA-2A (P) AND RIBAVIRIN (R) IN GENOTYPE 1 HCV TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS ARE SIMILAR. Journal of Hepatology. 52. S121–S122.
16.
Teperman, Lewis, James R. Spivey, F. Poordad, et al.. (2010). 28 EMTRICITABINE/TENOFOVIR DF COMBINATION +/− HBIG POST-ORTHOTOPIC LIVER TRANSPLANTATION TO PREVENT HEPATITIS B RECURRENCE IN PATIENTS WITH NORMAL TO MODERATE RENAL IMPAIRMENT: INTERIM RESULTS. Journal of Hepatology. 52. S12–S13.
17.
Poordad, F., John M. Vierling, Rafael Esteban, et al.. (2010). Hemoglobin Decline During Lead-in Phase as an Early Predictor of Anemia After the Addition of Boceprevir: A Retrospective Analysis of HCV SPRINT-1.
18.
Poordad, F., et al.. (2008). 996 TREATMENT WEEK 12 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAIVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS. Journal of Hepatology. 48. S373–S373.
19.
Tan, Henkie P., J. Stephen Dumler, Warren R. Maley, et al.. (2001). HUMAN MONOCYTIC EHRLICHIOSIS: AN EMERGING PATHOGEN IN TRANSPLANTATION. Transplantation. 71(11). 1678–1680.
20.
Tan, Henkie P., Jay S. Markowitz, Robert A. Montgomery, et al.. (2001). Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transplantation. 7(8). 745–749.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Roberto José de Carvalho‐Filho Breakdown of academic impact, for papers by Sergio Rodríguez‐Tajes Breakdown of academic impact, for papers by Marco Antonio Montes‐Cano Breakdown of academic impact, for papers by Cheng‐Chao Liang Breakdown of academic impact, for papers by Stanislas Pol Breakdown of academic impact, for papers by Petr Husa Breakdown of academic impact, for papers by J. Kirschner Breakdown of academic impact, for papers by Carlo Crivellaro Breakdown of academic impact, for papers by C. Cornù Breakdown of academic impact, for papers by C. Manegold